Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 3, 2011, Pages 150-152

  Nagayama, Hiroshi ^a   Ueda, Masayuki ^a   Kumagai, Tomoaki ^a   Tsukamoto, Kazuhisa ^a   Nishiyama, Yasuhiro ^a   Nishimura, Shungo ^a   Hamamoto, Makoto ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Ageing; Levodopa; Parkinson's disease; Pharmacokinetics

Indexed keywords

CARBIDOPA; LEVODOPA;

AGED; AGING; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPTOMATOLOGY; TABLET FORMULATION;

AGED; AGED, 80 AND OVER; AGING; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 79951553311     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.11.002     Document Type: Article

References (28)

1. Deleu D., Northway M.G., Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharm 2002, 41:261-309.
2. Gancher S.T., Nutt J.G., Woodward W.R. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987, 37:940-944.
3. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., Baruzzi A. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993, 43:367-371.
4. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiatr 1994, 57:672-681.
5. Murata M., Mizusawa H., Yamanouchi H., Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996, 103:1177-1185.
6. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
7. Morgante L., Rocca W.A., Di Rosa A.E., De Domenico P., Grigoletto F., Meneghini F., et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. Neurology 1992, 42:1901-1907.
8. Mclean A.J., Le Couteur D.G. Aging Biology and Geriatric clinical Pharmacology. Pharmacol Rev 2004, 56:163-184.
9. Contin M., Riva R., Martinelli P., Albani F., Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991, 41:463-466.
10. Robertson D.R., Wood N.D., Everest H., Monks K., Waller D.G., Renwick A.G., et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989, 28:61-69.
11. Evans M.A., Triggs E.J., Broe G.A., Saines N. Systemic activity of orally administered L-dopa in the elderly Parkinson patient. Eur J Clin Pharmacol 1980, 17:215-221.
12. Nagayama H., Hamamoto M., Nito C., Takagi S., Miyazaki T., Katayama Y. Initial symptoms of Parkinson's disease with elderly onset. Gerontology 2000, 46:129-132.
13. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 1988, 51:745-752.
14. Marttila R.J., Rinne U.K. Progression and survival in Parkinson's disease. Acta Neurol Scand 1991, 136(Suppl):24-28.
15. Kekki M., Samloff I.M., Ihamaki T., Varis K., Siurala M. Age- and sex-related behaviour of gastric acid secretion at the population level. Scand J Gastroenterol 1982, 17:737-743.
16. Evans M.A., Triggs E.J., Cheung M., Broe G.A., Creasey H. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981, 29:201-205.
17. Bender A. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965, 16:192-198.
18. Warren P.M., Pepperman M.A., Montgomery R.D. Age changes in small-intestinal mucosa. Lancet 1978, ii:849-850.
19. Corazza G.R., Frazzoni M., Gatto M.R., Gasbarrini G. Ageing and small-bowel mucosa: a morphometric study. Gerontology 1986, 32:60-65.
20. Gainsborough N., Maskrey V.L., Nelson M.L., Keating J., Sherwood R.A., Jackson S.H.D., et al. The association of age with gastric emptying. Age Ageing 1993, 22:37-40.
21. Husebye E., Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol 1992, 27:397-404.
22. Wade L.A., Katzman R. Synthetic amino acid and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem 1975, 25:837-842.
23. Gundert-Remy U., Hildebrandt R., Stiehl A., Weber E., Zürcher G., Da Prada M. Intestinal absorption of levodopa in man. Eur J Clin Pharmacol 1983, 25:69-72.
24. Gibaldi M., Boyes R.N., Feldman S. Influence of first-pass effect on avail-ability of drugs on oral administration. J Pharm Sci 1971, 60:1338-1340.
25. Iwamoto K., Watanabe J., Atsumi F. Age dependence in capacity-limited jejunal decarboxylation of levodopa in rats. Biochem Pharmacol 1987, 36:2151-2155.
26. Klawans H.L. Emerging strategies in Parkinson's disease. Neurology 1990, 40(Suppl. 3):1-76.
27. Kompoliti K., Adler C.H., Raman R., Pincus J.H., Leibowitz M.T., Ferry J.J., et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002, 58:1418-1422.
28. Muhlack S., Woitalla D., Welnic J., Twiehaus S., Przuntek H., Muller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004, 363:284-287.